Treatment of Chordoma with Isolated Local-Regional Relapse in the Mobile Spine or Sacrum
When chordoma recurs as an isolated local-regional relapse confined to the mobile spine or sacrum — without prior piecemeal resection, tumor rupture, or previous high-dose radiotherapy — management focuses on disease control and meaningful symptom relief.
Clinical Scenario
This protocol applies to chordoma with isolated local-regional relapse at the mobile spine or sacrum. The absence of prior piecemeal resection, tumor rupture, and prior high-dose radiotherapy at the site are defining eligibility criteria — these factors, when present, would exclude curative-intent re-resection and redirect to a different treatment pathway.
Primary Clinical Goal
Pain control and reduction of pain, including pain arising from epidural compression or nerve root involvement.
Treatment Approach (partial overview)
The approach combines palliative loco-regional interventions — spanning surgical, ablative, and radiation-based modalities — with best supportive care. Systemic therapy agents with documented evidence of activity in advanced chordoma are also part of the treatment landscape. The complete structured regimen, including sequencing, agent selection, and supporting evidence, is available via the link below.
References
DOI: 10.1093/annonc/mdx054
- Mobile spine/sacrum isolated local-regional relapse. A prior history of piecemeal resection (except for skull-base tumors where resection may be necessarily piecemeal), prior high-dose RT (in case of mobile spine and sacral chordoma), and/or tumor rupture are obvious exclusion criteria for re-resection with curative intent (IV-B).
- 'Salvage palliative/supportive treatment choices' include debulking surgery, low-dose RT, stereotactic body RT (SBRT), including radiosurgery to small volume, radiofrequency ablation (RFA) and other loco-regional approaches (i.e. cryotherapy), systemic therapy, PC and observation.
- Imatinib and sorafenib are the agents with the greatest evidence of efficacy in advanced chordoma and represent reasonable palliative treatment options to slow disease progression or alleviate symptoms (V*-B).
- In addition, several case reports have noted activity of sunitinib and EGFR inhibitors (cetuximab, erlotinib, gefitinib).
- Retrospective data suggest that cryoablation and RFA can be safe and useful palliative treatments in recurrent extracranial chordomas with a benefit in pain control.
View source ↗